Wooree BioLtd Balance Sheet Health
Financial Health criteria checks 6/6
Wooree BioLtd has a total shareholder equity of ₩251.1B and total debt of ₩63.9B, which brings its debt-to-equity ratio to 25.5%. Its total assets and total liabilities are ₩585.5B and ₩334.4B respectively. Wooree BioLtd's EBIT is ₩26.0B making its interest coverage ratio 11.7. It has cash and short-term investments of ₩123.7B.
Key information
25.5%
Debt to equity ratio
₩63.94b
Debt
| Interest coverage ratio | 11.7x |
| Cash | ₩123.74b |
| Equity | ₩251.10b |
| Total liabilities | ₩334.44b |
| Total assets | ₩585.54b |
Recent financial health updates
These 4 Measures Indicate That Wooree BioLtd (KOSDAQ:082850) Is Using Debt Reasonably Well
May 03
Here's Why Wooree BioLtd (KOSDAQ:082850) Can Manage Its Debt Responsibly
Feb 01
Recent updates
These 4 Measures Indicate That Wooree BioLtd (KOSDAQ:082850) Is Using Debt Reasonably Well
May 03Wooree Bio Co.,Ltd's (KOSDAQ:082850) Share Price Boosted 50% But Its Business Prospects Need A Lift Too
Apr 26Should You Invest In Wooree BioLtd (KOSDAQ:082850)?
Feb 28Here's Why Wooree BioLtd (KOSDAQ:082850) Can Manage Its Debt Responsibly
Feb 01Is Wooree Bio Co.,Ltd's (KOSDAQ:082850) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Jan 12Wooree BioLtd (KOSDAQ:082850) Shareholders Have Enjoyed A Whopping 478% Share Price Gain
Dec 21Here's Why We Think Wooree BioLtd's (KOSDAQ:082850) Statutory Earnings Might Be Conservative
Nov 29Financial Position Analysis
Short Term Liabilities: A082850's short term assets (₩452.7B) exceed its short term liabilities (₩317.1B).
Long Term Liabilities: A082850's short term assets (₩452.7B) exceed its long term liabilities (₩17.3B).
Debt to Equity History and Analysis
Debt Level: A082850 has more cash than its total debt.
Reducing Debt: A082850's debt to equity ratio has reduced from 120% to 25.5% over the past 5 years.
Debt Coverage: A082850's debt is well covered by operating cash flow (41.5%).
Interest Coverage: A082850's interest payments on its debt are well covered by EBIT (11.7x coverage).